The Sequencing Conundrum in Metastatic Castrate-resistant Prostate Cancer (mCRPC): the Rosemere Cancer Centre Experience to Unlocking the Optimal Sequence

被引：0
|
作者：
Pan, S. [1 ]
Kumar, V. [1 ]
Charnley, N. [1 ]
Parikh, O. [1 ]
Birtle, A. [1 ]
机构：
[1] Royal Preston Hosp, Rosemere Canc Ctr, Preston, Lancs, England
来源：
CLINICAL ONCOLOGY | 2016年 / 28卷 / 05期
关键词：
D O I：
10.1016/j.clon.2015.12.016
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：E14 / E14
页数：1
相关论文
共 50 条
  • [41] Sequencing in metastatic castrate-resistant prostate cancer with enzalutamide in a post-chemotherapy setting.
    Feinberg, Bruce A.
    Pandya, Bhavik
    Radtchenko, Janna
    Garofalo, David
    Flanders, Scott
    Brown, Bruce
    Barlev, Arie
    Bhor, Menaka
    JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)
  • [42] Updated analysis of a phase II study using sorafenib (S) for metastatic castrate-resistant prostate cancer (mCRPC)
    Aragon-Ching, J. B.
    Jain, L.
    Draper, D.
    Gulley, J. L.
    Arlen, P. M.
    Wright, J. J.
    Jones, E.
    Chen, C. C.
    Figg, W. D.
    Dahut, W. L.
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [43] Validation of a prognostic model for metastatic castrate-resistant prostate cancer (mCRPC) patients receiving abiraterone acetate (AA).
    Ravi, Praful Kumar
    Mateo, Joaquin
    Zafeiriou, Zafeiris
    Altavilla, Amelia
    Ferraldeschi, Roberta
    Sideris, Spyridon
    Grist, Emily
    Smith, Alan D.
    Wong, Sophia
    Lorente, David Look
    Bianchini, Diletta
    Attard, Gerhardt
    De Bono, Johann Sebastian
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [44] The impact of PSMA-positive circulating tumor cells in men with metastatic castrate-resistant prostate cancer (mCRPC)
    Gupta, S.
    Yang, Q.
    Halabi, S.
    Tubbs, A.
    Gore, Y.
    George, D. J.
    Nanus, D. M.
    Antonarakis, E. S.
    Danila, D.
    Szmulewitz, R.
    Wenstrup, R. J.
    Armstrong, A. J.
    ANNALS OF ONCOLOGY, 2022, 33 (07) : S1165 - S1166
  • [45] Racial disparities in metastatic castrate-resistant prostate cancer (mCRPC): Evidence from the Veterans Health Administration (VHA).
    Halwani, Ahmad
    Rasmussen, Kelli M.
    Patil, Vikas
    Burningham, Zachary
    Narayanan, Sujata
    Lin, Shih-Wen
    Carroll, Susheela
    Hsu, Ling-I
    Graff, Julie N.
    Dreicer, Robert
    Gupta, Sumati
    Low, Clarke
    Sauer, Brian C.
    CANCER RESEARCH, 2018, 78 (16) : 54 - 54
  • [46] PROTOTYPE MODEL IN METASTATIC CASTRATE-RESISTANT PROSTATE CANCER (MCRPC): A TOOL TO POSITION NEW TREATMENTS IN THE PATIENT PATHWAY?
    Karcher, H.
    Dinet, J.
    Amzal, B.
    Marteau, F.
    Obrzut, G.
    Pieniazek, I
    Brulais, S.
    Gabriel, S.
    VALUE IN HEALTH, 2013, 16 (07) : A593 - A593
  • [47] PSMA heterogeneity analysis in patients with metastatic castrate-resistant prostate cancer (mCRPC): Imaging versus CTCs.
    Morris, Michael J.
    Vogelzang, Nicholas J.
    Sartor, A. Oliver
    Armour, Alison A.
    Messmann, Richard Adam
    Groaning, Michael
    Robarts, Adam
    Tolcher, Anthony W.
    Gordon, Michael S.
    Babiker, Hani M.
    Kuo, Phillip
    Kearney, Megan
    Jendrisak, Adam
    Wang, Yipeng
    Landers, Mark Andrew
    Petrylak, Daniel Peter
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (06)
  • [48] Prognostic factors for patients with metastatic castrate-resistant prostate cancer (mCRPC) receiving abiraterone acetate prechemotherapy.
    Charnley, Natalie
    Birtle, Alison J.
    Swindell, Ric
    Parikh, Omi
    Wise, Marcus
    Kumar, Varadarajan
    Danwata, Falalu Dahiru
    Thompson, Catherine
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (15)
  • [49] Combination of PDL-1 and PARP inhibition in an unselected population with metastatic castrate-resistant prostate cancer (mCRPC).
    Karzai, Fatima
    Madan, Ravi Amrit
    Owens, Helen
    Hankin, Amy
    Couvillon, Anna
    Cordes, Lisa M.
    Fakhrejahani, Farhad
    Houston, Nicole D.
    Trepel, Jane B.
    Chen, Clara
    Edelman, Daniel C.
    Meltzer, Paul S.
    Steinberg, Seth M.
    Gulley, James L.
    Dahut, William L.
    Lee, Jung-min
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] High dose testosterone in men with metastatic castrate-resistant prostate cancer (mCRPC) and homologous recombination deficiency (HRD).
    Chen, Julia
    Joshua, Anthony M.
    Denmeade, Samuel R.
    Antonarakis, Emmanuel S.
    Crumbaker, Megan
    JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (15)
12345